• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    75th Annual Regeneron International Science and Engineering Fair Awards Teen Scientists from Around the World More Than $9 Million in 2025 Competition

    5/16/25 11:24:49 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $REGN alert in real time by email

    Adam Kovalčík, 19, receives $100,000 Top Award for his development of a medicine that can stop viruses from copying genes and controlling infections at the world's largest pre-college STEM competition in Columbus, Ohio

    TARRYTOWN, N.Y. and WASHINGTON, May 16, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Society for Science (the Society) announced that Adam Kovalčík, 19, of Dulovce, Slovakia, won the $100,000 George D. Yancopoulos Innovator Award at the 75th Regeneron International Science and Engineering Fair (Regeneron ISEF), the world's largest pre-college science and engineering competition. The award is named in honor of pioneering drug developer and Regeneron co-Founder, Board co-Chair, President and Chief Scientific Officer. Other top prizes went to projects in sustainable plastics engineering, air quality detection and advancement in prosthetics.

    The top winners were recognized during two award ceremonies: the Special Awards on May 15 and the Grand Awards Ceremony on May 16. In total, more than $9 million in awards and scholarships were distributed, honoring finalists for their creativity, innovative thinking and scientific rigor. The competition brought together nearly 1,700 young scientists representing 48 U.S. states and more than 60 countries, regions and territories.

    Adam Kovalčík, 19, of Dulovce, Slovakia, won first place and received the $100,000 George D. Yancopoulos Innovator Award for his new way of making the investigational antiviral drug galidesivir. Early clinical trials have shown this drug to be safe in humans. Animal tests show it may be effective against a broad spectrum of viruses. But it is expensive to produce. By starting with cheap materials from corn husk waste, he designed a shorter, more efficient way of making galidesivir. He cut the process from 15 to 10 steps and made almost twice as much drug in less time. He then used these reactions to create a new antiviral drug that may work even better. His new way to make these medicines can greatly decrease their cost, from $75/gram to about $12.50/gram. By making these medicines easier to produce, they are also easier to study, and if approved, more accessible, giving us more options to treat viral infections.

    Benjamin Davis, 16, of Wrentham, Massachusetts, received the $75,000 Regeneron Young Scientist Award for creating a desktop plastic recycling system. The user-friendly system can recycle 3D printer waste and other plastics. It turns them into filaments for 3D printing. Up to 67% of the filament used in a typical 3D printing project may end up as waste. Using electrical, mechanical and chemical engineering methods, Benjamin combined pultrusion (push-through) and extrusion (pull-through) processes. Together, this made the process about 45% more efficient. His device is faster than other home recyclers and creates a higher quality product. Its easy operation means nontechnical users can recycle and 3D print more efficiently. His design is an effective recycling machine that costs 90% less than commercial options.

    Siyaa Poddar, 16, of Chandler, Arizona, received the $75,000 Regeneron Young Scientist Award for her device, which rapidly detects toxic dusts. In the U.S. Southwest, toxic silica and uranium dusts from abandoned mines are a public health challenge. They contaminate the soil, air and groundwater, and can trigger autoimmune diseases like Sjögren's syndrome. Rates of Sjögren's syndrome are disproportionately high on Indigenous reservations in the Southwest, where many abandoned mines remain. Currently, there's no easy, fast or affordable way to measure how much of these toxins are in the air. Siyaa designed two low-cost detectors using chemicals that easily react with uranium or silica by changing color. She trapped these chemicals in a framework made of metal atoms and organic molecules to stabilize them. Her system is an affordable, easy-to-use way to monitor air quality.

    Samuel Skotnikov, 17, of Highland Village, Texas, and Chanyoung Kim and Eeshaan Prashanth, both 16, of Flower Mound, Texas, received the $50,000 Gordon E. Moore Award for Positive Outcomes for Future Generations for creating a brain-controlled bionic prosthetic leg. Current robotic limbs are expensive and can make movements feel unnatural. The team started by measuring the walking motion of their classmate, Aiden, with his usual prosthetic leg. They saw that the prosthetic's stiffness forced the remaining part of his amputated leg to work much harder than his other leg. They designed their prosthetic leg, Neuroflex, to read the wearer's brain signals through an EEG headband. The signals tell Neuroflex how the wearer wants to move, and Neuroflex uses its motors to support that movement. They also designed an ankle with more realistic joints. When the team tested their prototype on Aiden, it guessed the right movement 98% of the time. Their adaptable model could also relieve some of the cost burden of prosthetic limbs.

    "Congratulations to the winners of this year's Regeneron International Science and Engineering Fair," said Maya Ajmera, President and CEO of Society for Science and Executive Publisher of Science News. "I am deeply inspired by the creative, passionate and dedicated finalists from around the world who have come together—across borders, cultures and scientific disciplines —in the shared pursuit of science. Adam's research into antiviral medicines has the potential to change the impact and scale of how people can benefit from such important life-saving treatments. His research gives me great hope for the future of global health and scientific innovation."

    Now in its landmark 75th year, Regeneron ISEF remains the premier global stage for the next generation of scientists and engineers. This milestone year celebrates decades of scientific discovery, boundary-pushing innovation and international collaboration, uniting students from around the world in a powerful exchange of ideas. Through Regeneron ISEF and other STEM programming, Regeneron and the Society are fostering the next generation of STEM leaders who are pioneering solutions to improve our world. Since 2020, Regeneron has provided STEM experiences to over 3.2 million students, surpassing its goal of 2.5 million by 2025.

    "Congratulations to this year's extraordinary Regeneron ISEF finalists and winners," said George D. Yancopoulos, M.D., Ph.D., co-Founder, Board co-Chair, President and Chief Scientific Officer of Regeneron. "My own high school science project lit a fire in me that changed the course of my life. Today, I see these students carrying that same spark forward by asking bold questions, pushing boundaries and proving that innovative science can take on humanity's biggest challenges."

    Other top honors from the competition include:

    XinYan Chen, 17, of San Gabriel, California, received the $10,000 Craig R. Barrett Award for Innovation for her mobile indoor formaldehyde detector. Formaldehyde is a chemical found in many household goods that can cause disease, including cancer. Other detectors work by either trapping chemicals until they are full, or by breaking them down with expensive materials. XinYan designed a low-cost material that breaks down formaldehyde into carbon dioxide and water. She used the material to build a device that measures and destroys the poison at the same time. Her device lowered the amount of formaldehyde in a closed box by almost 90% in 18 hours. XinYan's device makes it cheaper and easier to both measure and improve indoor air quality.

    Aleksandra Petkova, 18, of Sofia, Bulgaria, received the $10,000 H. Robert Horvitz Prize for Fundamental Research for her research on the relationship between a boat's speed and the shape of its wake. When a boat travels faster than the waves it makes in the water, it makes a narrower wake. This type of wake creates more drag on the boat, which slows it down. Aleksandra looked at aerial photos of wakes and tested wake angles using a remote-controlled boat and a yacht. She figured out how to use a ship's size to predict the speed it can travel before it starts leaving a narrow wake. Aleksandra's ship wake model could help ship operators minimize drag by traveling at the ideal speeds for their ships.

    Cory Seelenfreund, 17, of New Rochelle, New York, received the $10,000 Peggy Scripps Award for Science Communication for his study of the relevance of memory in the Prisoner's Dilemma. Prisoner's Dilemma is a classic game theory problem where two people accused of a crime decide whether to snitch or stay silent. Cory created computer simulations and mathematical models to test how selfishness and memory affect the game. Memory of just one game often improved results, but players with better memory won in more complex scenarios. He found the best outcomes when players had a variety of self-interested and altruistic behaviors. These findings can help design smarter AI bots and other programs that need to "get along" with humans.

    Uma Sthanu, 17, of Austin, Texas, received the $10,000 Mary Sue Coleman Award for Life Science Innovation & Impact for her research on regenerating nerve cells. The neurons making up the human brain are powerful but fragile. Disease and injury can damage neurons and scientists have not yet found a way to regrow them. Uma studied the effects of an important hormone-like compound called PGE2 on damaged brain cells. She used advanced techniques to study how PGE2 treatment affects these broken neurons in the lab. She hopes this work will help researchers find better treatments for brain diseases and traumatic brain injuries.

    Pragathi Kasani-Akula, 17, of Cumming, Georgia; Aarushi Pandey, 17, of Conroe, Texas; and Vrishank Chandrasekhar, 18, of San Jose, California, received the Dudley R. Herschbach SIYSS Award, which provides finalists an all-expense paid trip to attend the Stockholm International Youth Science Seminar during Nobel Week in Stockholm, Sweden.

    Ethan Yan, 15, of Burlingame, California, and Abigail Qi, 16, of Baton Rouge, Louisiana, received the EU Contest for Young Scientists Award. Their projects will represent Regeneron ISEF at the EU Contest for Young Scientists to be held this September in Riga, Latvia.

    For more information about the top winners and access to visual assets visit our media kit: https://www.societyforscience.org/regeneron-isef-2025-media-kit/

    The full list of Special Award ISEF 2025 Finalists can be found at: https://www.societyforscience.org/press-release/regeneron-isef-2025-special-awards-winners

    In addition to the Top Award winners, more than 450 finalists received awards and prizes for their innovative research, including "First Award" winners, who each received a $6,000 prize.

    The following lists the First Award winners for each of the 22 categories, from which the Top Awards were chosen:

    Animal Sciences, sponsored by Society for Science

    • Matthew Lo, 16, of Berwyn, Pennsylvania

    Behavioral and Social Sciences, sponsored by Society for Science

    • Ameya Kharade, 16, of Nashua, New Hampshire
    • Jesse Rumball-Smith, 17, of Wellington, New Zealand

    Biochemistry, sponsored by Regeneron

    • Pragathi Kasani-Akula, 17, of Cumming, Georgia

    Biomedical and Health Sciences, sponsored by Regeneron

    • Edward Kang, 17, of Upper Saddle River, New Jersey
    • Uma Sthanu, 17, of Austin, Texas

    Biomedical Engineering, sponsored by Regeneron

    • Chanyoung Kim, 16, of Flower Mound, Texas
    • Eeshaan Prashanth, 17, of Flower Mound, Texas
    • Samuel Skotnikov, 17, of Highland Village, Texas

    Cellular and Molecular Biology, sponsored by Regeneron

    • Lilly Horowitz, 17, of Jericho, New York

    Chemistry, sponsored by Arc Institute

    • Adam Kovalčík, 19, of Dulovce, Slovakia

    Computational Biology and Bioinformatics, sponsored by Regeneron

    • Arnav Sharma, 15, of Troy, Michigan
    • Samarth Dunakhe, 15, of Chandler, Arizona
    • Aryav Das, 16, of Noblesville, Indiana
    • Qianheng Xu, 16, of Millburn, New Jersey

    Earth and Environmental Sciences, sponsored by Society for Science

    • Lakshmi Agrawal, 17, of Bellevue, Washington
    • Miriam Haddad, 18, of Saginaw, Michigan

    Embedded Systems, sponsored by HP

    • Maya Trutschl, 17, of Shreveport, Louisiana

    Energy: Sustainable Materials and Design, sponsored by Siemens Energy

    • Oliver Wang, 17, of Falls Church, Virginia

    Engineering Technology: Statics and Dynamics, sponsored by Howmet Aerospace Foundation

    • Benjamin Davis, 16, of Wrentham, Massachusetts

    Environmental Engineering, sponsored by Jacobs

    • Bennett Huang, 16, of Great Falls, Virginia
    • Jason Pan, 16, of Great Falls, Virginia
    • XinYan Chen, 17, of San Gabriel, California

    Materials Science, sponsored by Howmet Aerospace Foundation

    • Siyaa Poddar, 16, of Chandler, Arizona

    Mathematics, sponsored by Akamai Foundation

    • Cory Seelenfreund, 17, of New Rochelle, New York

    Microbiology, sponsored by Schattner Foundation

    • Abigail Qi, 16, of Baton Rouge, Louisiana

    Physics and Astronomy, sponsored by Jane Street

    • Aiden Kwon, 17, of Rolling Hills Estates, California                
    • Aleksandra Petkova, 18, of Sofia, Bulgaria

    Plant Sciences, sponsored by Society for Science

    • Aarushi Pandey, 17, of Conroe, Texas

    Robotics and Intelligent Machines, sponsored by Liquid AI

    • Chinmayi Goyal, 17, of Yorktown, New York
    • Timothy Wilson, 18, of Pennant Hills, Australia

    Systems Software, sponsored by Microsoft

    • Ram Sivaraman, 17, of Acton, Massachusetts

    Technology Enhances the Arts, sponsored by Midjourney

    • Punnawit Ponnirun, 17, of Chiang Mai, Thailand
    • Sataporn Thanapanyakul, 17, of Chiang Mai, Thailand
    • Siwakorn Suwannahong, 17, of Chiang Mai, Thailand

    Translational Medical Science, sponsored by Regeneron

    • Audrey Zheng, 16, of Wexford, Pennsylvania
    • Vrishank Chandrasekhar, 18, of San Jose, California

    The full list of all award-winning ISEF 2025 finalists is available here.

    View all the finalists' research here.

    About the Regeneron International Science and Engineering Fair

    The Regeneron International Science and Engineering Fair (Regeneron ISEF), a program of Society for Science celebrating 75 years, is the world's largest global science competition for high school students. Through a global network of local, regional and national science fairs, millions of students are encouraged to explore their passion for scientific inquiry. Each spring, a group of these students is selected as finalists and offered the opportunity to compete for approximately U.S. $9 million in awards and scholarships.

    In 2019, Regeneron became the title sponsor of ISEF to help reward and celebrate the best and brightest young minds globally and encourage them to pursue careers in STEM to positively impact the world. Regeneron ISEF is supported by a community of additional sponsors, Adam R. Scripps Foundation, Akamai Foundation, Aramco, Arc Institute, Gordon and Betty Moore Foundation, Howmet Aerospace Foundation, HP, Insaco, Intel, Jacobs, Jane Street, Liquid AI, Microsoft, Midjourney, Schattner Foundation, Siemens Energy, The Ohio State University, Battelle, Caltech, Cesco, Cisco, COSI, GoFundMe, Jeni's Splendid Ice Creams, JobsOhio, Johnson Energy Holdings. Many are entrepreneurs across a wide range of industries. Learn more at https://www.societyforscience.org/isef/.

    About Society for Science

    Society for Science is a champion for science, dedicated to promoting the understanding and appreciation of science and the vital role it plays in human advancement. Established in 1921, Society for Science is best known for its award-winning journalism through Science News and Science News Explores, its world-class science research competitions for students, including the Regeneron Science Talent Search, the Regeneron International Science and Engineering Fair and the Thermo Fisher Scientific Junior Innovators Challenge, and its STEM Outreach programming that seeks to ensure that all students have an opportunity to pursue a career in STEM. A 501(c)(3) membership organization, Society for Science is committed to inform, educate and inspire. Learn more at www.societyforscience.org and follow us on Facebook, Twitter, Instagram and Snapchat (Society4Science).

    About Regeneron

    Regeneron (NASDAQ:REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases and rare diseases.

    Regeneron believes that operating as a good corporate citizen is crucial to delivering on our mission. We approach corporate responsibility with three goals in mind: to improve the lives of people with serious disease, to foster a culture of integrity and excellence and to build sustainable communities. Regeneron is proud to be included on the Dow Jones Sustainability World Index and the Civic 50 list of the most "community-minded" companies in the U.S. Throughout the year, Regeneron empowers and supports employees to give back through our volunteering, pro-bono and matching gift programs. Our most significant philanthropic commitments are in the area of science education, including the Regeneron Science Talent Search and the Regeneron International Science and Engineering Fair (ISEF).

    For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

    Media Contacts

    Joseph Brown, Regeneron

    386-283-1323, [email protected]

    Gayle Kansagor, Society for Science

    703-489-1131, [email protected]



    Primary Logo

    Get the next $REGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $REGN

    DatePrice TargetRatingAnalyst
    5/14/2025$700.00Neutral → Buy
    Citigroup
    4/22/2025$695.00Overweight
    Cantor Fitzgerald
    2/5/2025$762.00 → $834.00Market Perform → Outperform
    Leerink Partners
    1/16/2025$1130.00 → $738.00Buy → Neutral
    UBS
    12/10/2024$565.00Underperform
    BofA Securities
    11/15/2024$1150.00Outperform
    Wolfe Research
    11/14/2024$895.00Neutral
    Citigroup
    9/24/2024$1175.00 → $1077.00Outperform → Market Perform
    Leerink Partners
    More analyst ratings

    $REGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 75th Annual Regeneron International Science and Engineering Fair Awards Teen Scientists from Around the World More Than $9 Million in 2025 Competition

      Adam Kovalčík, 19, receives $100,000 Top Award for his development of a medicine that can stop viruses from copying genes and controlling infections at the world's largest pre-college STEM competition in Columbus, Ohio TARRYTOWN, N.Y. and WASHINGTON, May 16, 2025 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. and Society for Science (the Society) announced that Adam Kovalčík, 19, of Dulovce, Slovakia, won the $100,000 George D. Yancopoulos Innovator Award at the 75th Regeneron International Science and Engineering Fair (Regeneron ISEF), the world's largest pre-college science

      5/16/25 1:29:00 PM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 75th Annual Regeneron International Science and Engineering Fair Awards Teen Scientists from Around the World More Than $9 Million in 2025 Competition

      Adam Kovalčík, 19, receives $100,000 Top Award for his development of a medicine that can stop viruses from copying genes and controlling infections at the world's largest pre-college STEM competition in Columbus, Ohio TARRYTOWN, N.Y. and WASHINGTON, May 16, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Society for Science (the Society) announced that Adam Kovalčík, 19, of Dulovce, Slovakia, won the $100,000 George D. Yancopoulos Innovator Award at the 75th Regeneron International Science and Engineering Fair (Regeneron ISEF), the world's largest pre-college science and engineering competition. The award is named in honor of pioneering drug developer and Regen

      5/16/25 11:24:49 AM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Regeneron Prevails over Amgen in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and Patient Access to Life-Saving Treatments

      Federal court jury found Amgen liable for violating antitrust and tort laws by using cross-therapeutic bundled rebates to prevent Praluent® (alirocumab) from competing in the market Jury awarded Regeneron $135.6 million dollars of compensatory damages and $271.2 million dollars in punitive damages TARRYTOWN, N.Y., May 15, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) applauds the jury verdict in the U.S. District Court for the District of Delaware that found that Amgen Inc. violated antitrust and tort laws by creating a bundling scheme that illegally leveraged its blockbuster anti-inflammatory drugs Enbrel® (etanercept) and Otezla® (apremilast) to convince ph

      5/15/25 2:02:43 PM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REGN
    SEC Filings

    See more
    • SEC Form 13F-HR filed by Regeneron Pharmaceuticals Inc.

      13F-HR - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)

      5/2/25 4:15:32 PM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Regeneron Pharmaceuticals Inc.

      10-Q - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)

      4/29/25 6:51:48 AM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Regeneron Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)

      4/29/25 6:37:44 AM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Schenkein David P was granted 166 shares, increasing direct ownership by 59% to 448 units (SEC Form 4)

      4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)

      1/6/25 5:42:19 PM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Thompson Craig B. was granted 166 shares, increasing direct ownership by 37% to 620 units (SEC Form 4)

      4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)

      1/6/25 4:13:03 PM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Coles N Anthony was granted 166 shares, increasing direct ownership by 12% to 1,559 units (SEC Form 4)

      4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)

      1/6/25 4:12:14 PM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Regeneron Pharma upgraded by Citigroup with a new price target

      Citigroup upgraded Regeneron Pharma from Neutral to Buy and set a new price target of $700.00

      5/14/25 8:51:04 AM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald resumed coverage on Regeneron Pharma with a new price target

      Cantor Fitzgerald resumed coverage of Regeneron Pharma with a rating of Overweight and set a new price target of $695.00

      4/22/25 7:34:24 AM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Regeneron Pharma upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded Regeneron Pharma from Market Perform to Outperform and set a new price target of $834.00 from $762.00 previously

      2/5/25 7:03:51 AM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REGN
    Financials

    Live finance-specific insights

    See more

    $REGN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025

      TARRYTOWN, N.Y., March 25, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2025 financial and operating results on Tuesday, April 29, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detai

      3/25/25 4:05:00 PM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025

      TARRYTOWN, N.Y., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2024 financial and operating results on Tuesday, February 4, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmati

      1/7/25 4:05:00 PM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024

      TARRYTOWN, N.Y., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2024 financial and operating results on Thursday, October 31, 2024, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email deta

      9/26/24 4:05:00 PM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • May 20, 2022 - FDA Approves First Treatment for Eosinophilic Esophagitis, a Chronic Immune Disorder

      For Immediate Release: May 20, 2022 Today, the U.S. Food and Drug Administration approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in adults and pediatric patients 12 years and older weighing at least 40 kilograms (which is about 88 pounds). Today’s action marks the first FDA approval of a treatment for EoE. “As researchers and clinicians have gained knowledge about eosinophilic esophagitis

      5/20/22 3:11:09 PM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Regeneron Pharmaceuticals Inc. (Amendment)

      SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)

      2/13/24 5:12:22 PM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Regeneron Pharmaceuticals Inc. (Amendment)

      SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)

      2/9/24 6:19:03 PM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Regeneron Pharmaceuticals Inc. (Amendment)

      SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)

      2/9/24 9:49:31 AM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs

      TARRYTOWN, N.Y., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the formation of Regeneron Cell Medicines based on an agreement with 2seventy bio, Inc. to acquire full development and commercialization rights to its pipeline of investigational novel immune cell therapies, along with its discovery and clinical manufacturing capabilities. 2seventy bio employees who support the acquired programs will join Regeneron Cell Medicines, a newly formed research & development (R&D) unit to advance cell therapies and combination approaches in oncology and immunology. "Regeneron and 2seventy share a relentless commitment to push the boundaries of scie

      1/30/24 7:00:41 AM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry

      NIH data show that globally less than 2% of genetic information being studied today originates from people of African ancestry1 The newly established Diaspora Human Genomics Institute (DHGI) will manage the Together for CHANGE initiative, which aims to increase available genomic data for people of African ancestry and enhance representation in STEM careers NASHVILLE, Tenn. and TARRYTOWN, N.Y. and WILMINGTON, Del. and BAGSVAERD, Denmark and BASEL, Switzerland, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Meharry Medical College, along with partners Regeneron Genetics Center® (RGC™), AstraZeneca, Novo Nordisk, and Roche, today announced the launch of the Together for CHANGE™ ("Changing Healthcare for

      10/18/23 9:00:00 AM ET
      $AZN
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Regeneron Announces Retirement of Board Chair, Dr. P. Roy Vagelos, Accomplished Physician-Businessman and Industry Luminary

      TARRYTOWN, N.Y., April 17, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that P. Roy Vagelos, M.D., will retire from his role as Chair of the Company's Board of Directors and will not stand for reelection at the Company's 2023 Annual Meeting of Shareholders. Dr. Vagelos has served as Chair since January 1995 and will complete his current term through the conclusion of the Annual Meeting on June 9, 2023. Effective upon the conclusion of that meeting, the Board plans to appoint Leonard S. Schleifer, M.D., Ph.D., and George D. Yancopoulos, M.D., Ph.D., as Co-Chairs of the Board, in addition to their roles as President and Chief Executive Officer and P

      4/17/23 7:30:00 AM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care